
Phase 3 MAESTRO-NAFLD-1 Data for Resmetirom in MASH Cirrhosis, with Naim Alkhouri, MD
In 2024, the US Food and Drug Administration granted accelerated approval to Madrigal Pharmaceuticals’ resmetirom (Rezdiffra) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in patients with moderate to advanced …